In depression, rapamycin pretreatment before ketamine failed to blunt the acute antidepressant response and may have prolonged benefit, indicating pathway modulation without establishing mTOR hyperactivity as a primary causal driver [72]. The gene discussed is MTOR; the disease is depressive symptom measurement.